Active, not recruiting
A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment
NCT07567352
- Conditions
- ALK-positive Advanced NSCLC, ALK-positive NSCLC, ALK-positive Non-small-cell Lung Cancer, +11 more
- Locations
-
- Pfizer New York, United States